Browsing by Autor "Pandelis Perakakis"

Now showing 1 - 4 of 4

HEPLAB: Matlab scripts for heartbeat-evoked potential analysis
(Figshare (United Kingdom), 2018) Pandelis Perakakis; Luís F. Ciria
Scripts to facilitate the analysis of the heartbeat evoked potential using eeglab and fieldtrip. The scripts use sample data that can become available upon request. Researchers with some experience with eeglab, however, will find it easy to adapt the scripts to their data without having to use additional resources.
The relationship between vigilance capacity and physical exercise: A mixed-effects multistudy analysis
(2018) Daniel Sanabria; Antonio Luque‐Casado; José C. Perales; Rafa; Luís F. Ciria; Florentino Huertas; Pandelis Perakakis
A substantial body of work has depicted a positive association between physical exercise and cognition, although the key factors driving that link are still a matter of scientific debate. Here, we aimed to contribute further to that topic by pooling the data from seven studies (N=361) conducted by our research group to examine whether cardiovascular fitness (VO2), sport type participation (externally-paced [e.g., football or basketball] and self-paced [e.g., triathlon or track and field athletes] vs. sedentary), or both, are crucial factors to explain the association between the regular practice of exercise and vigilance capacity. We controlled for relevant variables such as age and the method of VO2 estimation. The Psychomotor Vigilance Task was used to measure vigilance performance by means of reaction time (RT). The results showed that externally-paced sport practice (e.g., football) resulted in significantly shorter RT compared to self-paced sport (e.g., triathlon) and sedentary condition, depicting larger effects in children and adolescents than in adults. Further analyses revealed no significant effect of cardiovascular fitness and self-paced sport practice, in comparison to the sedentary condition, on RT. Our data point to the relevance of considering the type of sport practice over and above the level of cardiovascular fitness as crucial factor to explain the positive association between the regular practice of exercise and vigilance capacity.
Tramadol effects on physical performance and sustained attention during a 20-min indoor cycling time-trial: A randomised controlled trial
(Elsevier BV, 2018) Darías Holgado; Thomas Zandonai; Míkel Zabala; James Hopker; Pandelis Perakakis; Antonio Luque‐Casado; Luís F. Ciria; Eduardo Guerra‐Hernández; Daniel Sanabria
Objectives: To investigate the effect of tramadol on performance during a 20-min cycling time-trial (Exper- iment 1), and to test whether sustained attention would be impaired during cycling after tramadol intake (Experiment 2). Design: Randomized, double-blind, placebo controlled trial. Methods: In Experiment 1, participants completed a cycling time-trial, 120-min after they ingested either tramadol or placebo. In Experiment 2, participants performed a visual oddball task during the time-trial. Electroencephalography measures (EEG) were recorded throughout the session. Results: In Experiment 1, average time-trial power output was higher in the tramadol vs. placebo condition (tramadol: 220 W vs. placebo: 209 W; p < 0.01). In Experiment 2, no differences between conditions were observed in the average power output (tramadol: 234 W vs. placebo: 230 W; p > 0.05). No behavioural differences were found between conditions in the oddball task. Crucially, the time frequency analysis in Experiment 2 revealed an overall lower target-locked power in the beta-band (p < 0.01), and higher alpha suppression (p < 0.01) in the tramadol vs. placebo condition. At baseline, EEG power spectrum was higher under tramadol than under placebo in Experiment 1 while the reverse was true for Experiment 2. Conclusions: Tramadol improved cycling power output in Experiment 1, but not in Experiment 2, which may be due to the simultaneous performance of a cognitive task. Interestingly enough, the EEG data in Experiment 2 pointed to an impact of tramadol on stimulus processing related to sustained attention. Trial registration: EudraCT number: 2015-005056-96.
Tramadol effects on physical performance and sustained attention during a 20-min indoor cycling time-trial: A randomised controlled trial
(European Organization for Nuclear Research, 2018) Darías Holgado; Thomas Zandonai; Míkel Zabala; James Hopker; Pandelis Perakakis; Antonio Luque‐Casado; Luís F. Ciria; Eduardo Guerra‐Hernández; Daniel Sanabria
Objectives: To investigate the effect of tramadol on performance during a 20-min cycling time-trial (Exper- iment 1), and to test whether sustained attention would be impaired during cycling after tramadol intake (Experiment 2). Design: Randomized, double-blind, placebo controlled trial. Methods: In Experiment 1, participants completed a cycling time-trial, 120-min after they ingested either tramadol or placebo. In Experiment 2, participants performed a visual oddball task during the time-trial. Electroencephalography measures (EEG) were recorded throughout the session. Results: In Experiment 1, average time-trial power output was higher in the tramadol vs. placebo condition (tramadol: 220 W vs. placebo: 209 W; p < 0.01). In Experiment 2, no differences between conditions were observed in the average power output (tramadol: 234 W vs. placebo: 230 W; p > 0.05). No behavioural differences were found between conditions in the oddball task. Crucially, the time frequency analysis in Experiment 2 revealed an overall lower target-locked power in the beta-band (p < 0.01), and higher alpha suppression (p < 0.01) in the tramadol vs. placebo condition. At baseline, EEG power spectrum was higher under tramadol than under placebo in Experiment 1 while the reverse was true for Experiment 2. Conclusions: Tramadol improved cycling power output in Experiment 1, but not in Experiment 2, which may be due to the simultaneous performance of a cognitive task. Interestingly enough, the EEG data in Experiment 2 pointed to an impact of tramadol on stimulus processing related to sustained attention. Trial registration: EudraCT number: 2015-005056-96.